Initial Consultation of Patients With Advanced Endometrial Cancer

The FDA has approved tisotumab vedotin-tftv for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Older patients with cancer demonstrated a moderate to high symptom burden, leading to the need for routine symptom assessments and tailored management interventions.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Throughout March, the FDA has approved drugs for the treatment of disease including lung, hematologic, esophageal, and gynecologic cancers.

Criteria for progression-free and overall survival endpoints in patients with endometrial cancer with mismatch repair proficient disease were not met.